QingAnXin 晴安欣 (Avatrombopag) 20mg*10 Tablets | NJCTTQ First Generic | GLT

Generic Information: QingAnXin (Avatrombopag) — First Chinese Generic, Nanjing Chia Tai Tianqing

QingAnXin (晴安欣) holds a specific place in this drug family's Chinese history: it was the first avatrombopag generic approved in mainland China, winning both first-generic status and the first pass of consistency evaluation in a single stroke at the end of 2023. The maker is Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. — NJCTTQ, the robust generics-and-innovation arm of Sino Biopharmaceutical — an outfit that has collected first-generic titles across eight products. Each box carries approval number 国药准字H20234563 and holds ten 20 mg film-coated tablets, matching the originator's strength exactly.

What Is QingAnXin (Avatrombopag) Used For?

It treats the same two adult populations as the original: thrombocytopenia of chronic liver disease ahead of elective procedures, where a short course averts platelet transfusion and surgical delay; and chronic primary immune thrombocytopenia in adults who stopped responding to steroids or immunoglobulin, where the goal is durable counts above 50×10⁹/L with fewer bleeding events. For Chinese hepatology centers the arrival of a domestic first generic turned a hospital-only, import-budget drug into something a county hospital pharmacy could stock — access, not just price, is what first-generic status changed.

How Does QingAnXin (Avatrombopag) Work?

Avatrombopag is an orally active, non-peptide thrombopoietin receptor agonist of the second generation. It stimulates c-Mpl receptors on megakaryocytes from a binding site in the receptor's transmembrane domain, driving the proliferation and differentiation that end in new circulating platelets. Because its binding does not overlap with natural thrombopoietin, the two signals sum; and because the molecule leaves metal ions alone, there is no chelation problem — food, milk and mineral supplements do not need scheduling around doses.

Indications of QingAnXin (China Label)

The package insert lists: adults with chronic liver disease related thrombocytopenia scheduled for elective diagnostic procedures or surgery; and adults with chronic primary immune thrombocytopenia who had insufficient response to previous treatment, for raising platelet counts and reducing or preventing bleeding. The insert also repeats the boundary that cirrhotic patients should not use it simply to chase normal counts. NJCTTQ's regulatory filings for the drug document the full CLD-plus-ITP dual indication the parent originator established.

Dosage and Administration

One dose daily, swallowed whole with food. For the CLD course the count decides the size: below 40×10⁹/L take three tablets (60 mg) daily; between 40 and below 50×10⁹/L take two (40 mg) — five consecutive days, starting ten to thirteen days before the scheduled procedure, which then follows five to eight days after the last tablet. For ITP, start at one tablet daily; titrate to keep platelets at or above 50×10⁹/L and never exceed two tablets (40 mg) in a day. Counts are checked weekly early in treatment; a skipped tablet is taken when remembered, and the next day continues as planned.

Side Effects of QingAnXin

The commonest reports mirror the class: fever, abdominal discomfort, nausea, headache, weariness and ankle swelling in CLD patients; headache, fatigue, contusions, nosebleeds, gum bleeding, joint aches, pinpoint skin spots and cold symptoms in ITP patients. Thrombosis is the flagged serious risk — counts are tracked, doses are cut if platelets overshoot, and any chest pain, breathlessness or painful limb swelling is an emergency signal. Liver enzyme rises have appeared in trial monitoring, so physicians often re-check liver panels alongside counts.

Storage Instructions

Keep the tablets in the original box at room temperature, dry and out of strong light, sealed until use. No cold chain. Store away from children, and dispose of leftover tablets through a pharmacy rather than household trash.

Why Choose QingAnXin from GLT?

QingAnXin is the brand many Chinese hepatologists already know by name — first to market among generics, backed by one of the country's largest listed pharma groups, and carrying a clear provenance trail (H20234563) that customs and clinic pharmacists verify without friction. GLT ships sealed NJCTTQ boxes worldwide with pre-shipment photographs, offers honest side-by-side quotations against the imported original and the Southeast Asian generics, and answers every message personally — WhatsApp +86 15234153837, email [email protected] — from first question to delivered carton.

How to Order QingAnXin (Avatrombopag)

Contact GLT on WhatsApp +86 15234153837 or at [email protected] with your required quantity and destination. Expect a formal quotation with shipping and payment options within one working day; confirmed orders leave with complete export paperwork, and repeat ITP therapy can be placed on a standing monthly schedule.

FAQ

What does "first generic" (首仿) actually mean here? Nanjing Chia Tai Tianqing was the first company whose avatrombopag generic cleared China's regulatory review, setting the benchmark other domestic filings followed.

Who is behind NJCTTQ? Nanjing Chia Tai Tianqing Pharmaceutical operates under Sino Biopharmaceutical, one of China's largest listed pharmaceutical groups, with its own innovation pipeline on top of the generics engine.

Is 晴安欣 the same strength as the imported original? Yes — 20 mg film-coated tablets, ten to the box, evaluated for consistency against the originator reference standard.

How is the five-day CLD course timed? Start ten to thirteen days before the procedure and finish the five doses; the operation then falls five to eight days after the final tablet, right at the count peak.

What if platelets overshoot on ITP therapy? The doctor steps the dose down or pauses — above roughly 200×10⁹/L the dose drops a level, and the drug stops entirely if counts climb beyond 400×10⁹/L, resuming lower once counts settle.